Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $21.00.
據Marketbeat.com報道，異基因治療公司(納斯達克代碼：ALLO-GET Rating)目前覆蓋該公司的12家評級公司的平均評級為“中等買入”。一名投資分析師對該股的評級為賣出，一名分析師給出了持有評級，九名分析師給出了該公司的買入評級。在過去一年裏追蹤該股的經紀商中，1年的平均目標價為21.00美元。
Several analysts recently issued reports on ALLO shares. HC Wainwright reduced their price target on shares of Allogene Therapeutics from $43.00 to $29.00 and set a "buy" rating on the stock in a research report on Monday, November 21st. Bank of America lowered shares of Allogene Therapeutics from a "buy" rating to an "underperform" rating and reduced their price target for the stock from $24.00 to $9.00 in a research report on Monday, December 12th. Oppenheimer reissued an "outperform" rating and issued a $32.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, December 1st. JPMorgan Chase & Co. raised shares of Allogene Therapeutics from a "neutral" rating to an "overweight" rating and dropped their price objective for the company from $20.00 to $11.00 in a research note on Tuesday. Finally, Robert W. Baird raised shares of Allogene Therapeutics from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research note on Friday, January 6th. They noted that the move was a valuation call.
幾位分析師最近發佈了關於Allo股票的報告。HC Wainwright在11月21日星期一的一份研究報告中將他們對異體基因治療公司股票的目標價從43.00美元下調至29.00美元，並對該股設定了“買入”評級。美國銀行在12月12日(星期一)的一份研究報告中將allgene Treeutics的股票評級從“買入”下調至“表現不佳”，並將該股的目標價從24.00美元下調至9.00美元。奧本海默在12月1日星期四的一份研究報告中重新發布了“跑贏大盤”的評級，併為異基因治療公司的股票發佈了32.00美元的目標價。週二，摩根大通在一份研究報告中將阿羅吉恩治療公司的股票評級從中性上調至增持，並將該公司的目標價從20.00美元下調至11.00美元。最後，羅伯特·W·貝爾德在1月6日星期五的一份研究報告中將異基因治療公司的股票評級從中性上調至“跑贏大盤”，併為該公司設定了12.00美元的目標價。他們指出，此舉是一次估值預測。
Insider Activity
內幕活動
In other news, General Counsel Veer Bhavnagri sold 5,602 shares of the firm's stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $7.53, for a total transaction of $42,183.06. Following the completion of the transaction, the general counsel now owns 583,677 shares of the company's stock, valued at $4,395,087.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 29.80% of the company's stock.
在其他新聞方面，總法律顧問Veer Bhavnagri在12月15日星期四的一次交易中出售了5602股該公司的股票。這些股票以7.53美元的平均價格出售，總成交額為42,183.06美元。交易完成後，總法律顧問現在擁有該公司583,677股股票，價值4,395,087.81美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過此超鏈接。內部人士持有該公司29.80%的股份。
Hedge Funds Weigh In On Allogene Therapeutics
對衝基金參與同種異體基因治療
Allogene Therapeutics Trading Up 15.7 %
同種異體基因治療藥物交易上漲15.7%
NASDAQ ALLO opened at $7.94 on Wednesday. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.61 and a beta of 0.71. The firm's 50 day simple moving average is $7.70 and its 200 day simple moving average is $10.81. Allogene Therapeutics has a 1 year low of $5.41 and a 1 year high of $17.49.
納斯達克週三開盤報7.94美元。該公司市值11.5億美元，市盈率為-3.61倍，貝塔係數為0.71。該公司的50日簡單移動均線為7.70美元，200日簡單移動均線為10.81美元。異基因治療公司的一年低點為5.41美元，一年高位為17.49美元。
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.04. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.01 million. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same quarter last year, the business posted ($0.57) EPS. On average, equities research analysts forecast that Allogene Therapeutics will post -2.38 earnings per share for the current year.
異基因治療公司(納斯達克：ALLO-GET評級)最近一次公佈季度收益結果是在11月2日星期三。該公司公佈本季度每股收益(EPS)為0.58美元，比普遍預期的0.62美元高出0.04美元。該業務本季度營收為5萬美元，而分析師預期為10萬美元。同種基因治療公司的淨利潤率為負126580.16%，淨資產回報率為負37.74%。去年同一季度，該業務公佈了每股收益(0.57美元)。平均而言，股票研究分析師預測，異基因治療公司本年度的每股收益將達到2.38美元。
About Allogene Therapeutics
關於同種異體基因療法
(Get Rating)
(獲取評級)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
異體基因治療公司是一家臨牀階段免疫腫瘤學公司，開發並商業化用於癌症治療的基因工程同種異體T細胞療法。它開發、製造和商業化UCART19，這是一種同種異體嵌合抗原受體(CAR)T細胞產品，用於治療R/R CD19陽性B細胞ALL的兒童和成人患者。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
- 免費獲取StockNews.com關於同種異體基因治療的研究報告(ALLO)
- 柔順治療公司的差距增加了34%：未來還會有更多的好處嗎？
- 2023年初裁員將如何影響這5只生物科技股？
- Baudax Bio投資者在經歷了70%的飆升後，痛苦是否已經結束？
- 火箭實驗室的首次美國發射將把斯托克送入平流層嗎？
- 2023年響亮登場的3只零售股
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《同種異體基因治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對異種基因治療公司和相關公司評級的每日簡要摘要。